The critical role of antigen-specific T cells in cancer immunotherapy has been amply demonstrated in many model systems. Though success of clinical trials still remains far behind expectation, the continuous improvement in our understanding of the biology of the immune response will provide the basis of optimized cancer vaccines and allow for new modalities of cancer treatment. This review focuses on the current status of active therapeutic vaccination and future prospects. The latter will mainly be concerned with allogeneic bone marrow cell transplantation after non-myeloablative conditioning, because it is my belief that this approach could provide a major breakthrough in cancer immunotherapy.
Introduction
The concept of immunotherapy of cancer has been evoked more than a century ago by W. Coley (1) . Yet, it is only recently that the state of knowledge allows for molecularly defined therapeutic approaches and much effort will still be required to place immunotherapy beside of surgery, chemotherapy and radiation as a fourth option. Although conventional tumor therapies have been steadily improved during the last decades, mortality due to cancer is still high and, thus, supplemental and complementary therapeutic strategies are clearly needed. Most promising approaches are the blockade of neo-angiogenesis (2), modulation of matrix degrading enzymes (3), cancer gene therapy (4) and immunotherapeutic procedures aiming at molecularly defined target tumor antigens (5, 6) . This review will focus on active vaccination in therapeutic settings. This is not to neglect preventive vaccination, which will be a possible option for tumors with a proven viral etiology, e.g., cervical carcinoma which results from an infection with human papilloma virus (7) . In such instances, vaccination aims to eliminate the viral infection in a state of premalignant affection and to prevent the process of tumorigenic transformation. Cancer immunoprevention can also be considered for tumor-associated antigens, which are a prerequiste for tumor formation and as such are persistent tumor antigens (8, 9) . The concept of immunotherapy of cancer by active vaccination offers several advantages, which are neither provided by conventional therapies nor by unspecific immunostimulation: Effector T cells should i) be effective against both proliferating and non-proliferating (i.e. dormant) tumor cells; ii) selectively attack the tumor, which implies no or minimal side effects; iii) act systemically against primary as well as dispersed tumor cells and iv) be endowed with a memory allowing for a persisting attack of the tumor and/or a rapid and efficient reactivation in case of recurrence (10). In the past and due to the long-lasting ignorance of tumor antigens, clinical trials have mostly been concerned with modes of unspecific immunomodulation. Although response modifiers do not have the above mentioned advantages, a new generation of adjuvant has evolved, which is conceived to support the adaptive immune system and therefore have become, in combination with active vaccination, an important and far more efficacious factor than by itself (11, 12) .
Hematopoietic stem cell reconstitution has originally been restricted exclusively to autologous bone marrow cells or peripheral blood stem cells, which have been reinfused into the myeloablatively conditioned patient after purging. The approach is burdened by the danger of reinjecting residual tumor cells. Nevertheless, it helped to decrease the tumor burden, although it did not contribute to initiate or strengthen an anti-tumor immune defense (13). This is different when tumor patients are reconstituted with allogeneic hematopoietic stem cells, where the graft will react against the host, but also against the tumor. How to minimize graft versus host disease (GvHD), but to maintain graft versus tumor (GvT) reactivity is still a matter of debate and will possibly be achieved in combination with an active vaccination regimen (14) . Interest in the approach of allogeneic hematopoietic stem cell transplantation has gained significantly, since it was demonstrated that myeloablative conditioning is by no means a conditio sine qua non. First clinical trials have shown that an allogeneic graft can be accepted by non-myeloablatively conditioned patients. Using those regimen, an allogeneic transplant can be given to elderly patients and patients in poor health condition (15) . Yet, even with such mild conditioning regimen, the problem of how to reduce GvHD, but to sustain GvT reactivity remains. Finally, it should be mentioned that tumor cells do not at all represent an optimal target for the immune system. This relies on peculiarities of the tumor, such as immune escape or tumor counterattack (16, 17) , but also on the limited suitability of the immune system to recognize and respond to tumor antigens (18, 19) . Particularly the latter aspect may well be overcome in the allogeneically reconstituted patient. dental, as reviewed in (20, 28, 29) . Melanoma associated antigens are represented by Melan A, tyrosinase and gp100 which are also expressed on normal melanocytes. An efficient immune response against these antigens will invariably lead to a damage of the melanocytes. Obviously, an elimination of cognate normal cells, i.e. melanocytes, may be tolerated in this instance , but may give rise to severe side effects in a number of other instances (e.g., mucosal cells). On the other hand, differentiation antigens are not necessarily indispensable for the respective tumors. Two therapeutically important consequences arise from this fact: i) the expression of these antigens may be heterogeneous in different tumors of the same histology and even within an individual tumor; ii) a loss of the antigen may not be detrimental to the malignant phenotype such that antigen-loss variants may emerge and dominate under the selective pressure of the immune attack.
An important group of tumor-associated antigens goes under the name of "cancer testis antigens" (30-32), the prototypes being the members of the MAGE family (33, 34) . These are expressed in a number of tumors, but also in testis and placenta. The latter tissues are immune-privileged in the sense that they are not subjected to immune surveillance and that tissue-specific antigens are "unknown" to the immune system. Due to this special situation, MAGE antigens can be regarded as "functionally tumor-specific".
Another group of tumor antigens are viral and virally-induced antigens, e.g., HPV-induced antigens in cervix carcinoma. Once a virus is the central element of tumor etiology, all cells will carry the same virus-related antigens while non-infected cells will be negative. Virally-induced antigens therefore are of major importance in tumor vaccination (7, 35, 36) .
Vaccination Strategies
Even when tumor cells do express immunogenic antigens, patients bearing those tumors obviously do not mount a successful anti-tumor response spontaneously. The reasons for this can be manifold and will be discussed later. Hence, an extrinsic stimulus is mandatory to overcome the state of nonresponsiveness. Several modes of confronting the immune system with tumor antigens have been proposed.
Undefined Tumor Antigens -Tumor Cell Vaccines
The most advanced therapeutic tumor vaccine, Melacine®, is composed of two melanoma cell line lysates in combination with commercial adjuvant Detox™ (37). It has been approved for commercial sale in North America. In Phase III trials, response rates of melanoma patients to the vaccine were below the ones to a standard four-drug chemotherapy, but side effects were fewer and milder and the overall survival rate was similar. In a recently published study, Cancer Vax together with BCG has been given to patients with advanced colon cancer which were refractory to standard therapy. It was found that the vaccine can induce a humoral and a cellular response, which correlates with the overall survival time (38). In melanoma patients, it has been described that particularly those which become positive for TA90 antigen-antibody complexes have a significantly improved disease free and overall survival rate (39).
The approach of vaccinating with genetically modified autologous tumor cells (40) has followed the double goal of increasing the potency and of addressing exactly the combination of tumor antigens which are expressed in the individual patient. A number of conceptually different technologies have been proposed: to provide a vigorous peptide presentation, tumor cells have been transfected with MHC class I genes (41, 42) for the induction of T cell cytotoxicity or with class II genes (43-45) for the induction of T cell help. To facilitate the activation of lymphocytes, transfection with cDNA of costimulatory molecules, mainly B7, has been evaluated (45-48). Alternatively, cytokine genes have been transduced into autologous tumor cells to promote the in vivo expansion of the tumor-recognizing lymphocytes in close vicinity of tumor antigens presented on the surface of the cytokine-transduced cell (45, (49) (50) (51) (52) (53) . In clinical trials with an autologous tumor vaccine, tumor cells have either been heterogenized or mixed with BCG or both (54-58). The latter has been reported to significantly improve the therapeutic efficacy (57), although the overall prolongation of disease-free intervals and on survival time proved to be quite variable (59). There are several reports on successful short term culture of tumor cells for an autologous vaccine (60). Yet, the propagation of an autologous vaccine with subsequent genetic modification will succeed only exceptionally. Therefore, vaccination with allogeneic cells, which has been discussed and practiced for several years (61) is currently coming into focus again. Animal studies report on strong effects with activation of TH and CTL (62, 63) . In the human system, too, induction of tumor-specific CTL besides alloantigen-specific CTL has been described (64). However, it remains to be explored how such an allogeneic vaccine can efficiently initiate a MHC-restricted, tumor antigen-specific immune response. Nonetheless, all these approaches share the advantage of being independent of knowing molecularly defined tumor antigens.
Molecularly Defined Tumor Antigen -DNA/RNA/Protein Vaccination
The use of molecularly defined antigens for vaccination has helped a lot in understanding the mechanisms of inducing and sustaining a therapeutic immune response. Most of the initial work was based on the subcutaneous or intradermal administration of antigen preparations, either whole proteins or peptides comprising the immunogenic epitopes, together with a variety of immune adjuvants. However, this procedure, though being technically easy, has not yet reached the level of reproducibly inducing significant response rates in groups of tumor patients. Hence, the process of searching for improved vaccination strategies is by no means completed and, understandably, comparative evaluations of different vaccination schedules are completely missing in patients, but in a strict sense also in animal models (65) (66) (67) . Concerning the form of the antigen, current protocols use either vaccination with cDNA (68-74), RNA (69, 72, 75) , proteins or peptides (76-79).
DNA Vaccination
Advances in gene transfer technologies have opened new avenues in cancer gene therapy, although the ideal approach remains to be determined and may vary with the tumor type (80-82). DNA vaccines induce immune responses by direct expression of the antigenic proteins in the host. Delivery of naked DNA mostly follows either the intramuscular or the intradermal route. DNA is given intramuscularly in a saline solution, while DNA-coated gold beads are delivered intradermally via gene gun. It is supposed that by the intradermal route DCs are directly transfected, while after intramuscular application both monocytes and DCs may become targets. Transcription can be observed rather rapidly and may last for about one month. After intramuscular application, both TH1 and TH2 responses have been recorded, depending on whether the antigen is a secretory product (TH2 response) or an intracellular or membrane anchored molecule (TH1). After gene gun delivery mainly TH2 responses have been observed (83-85). In addition, certain DNA motifs (CpG) are known to be immunostimulatory and strongly augment the amplitude of immune response (84, (86) (87) (88) .
Alternative routes of application as well as packaging of DNA may expand the field of application and strengthen the immunostimulatory potential. Packaging of DNA in attenuated salmonella or listeria has opened the way for oral application (89, 90) . These bacteria can cross the epithelial barrier of the gut and will be taken up by macrophages in the peritoneal cavity, where they survive for a limited number of cell cycles. It has been described that the DNA introduced into the bacteria will be transcribed in the host cells, which either present the antigen directly or eventually may die such that DC will take up the cell debris and present resulting peptides preferentially (though not exclusively) on MHC class II molecules. Monocytes which have ingested the bacteria will present the molecules in the context with MHC class I molecules. These features explain why after DNA vaccination via a bacterial transporter TH as well as CTL responses and antibody production can be observed (91, 92) . This oral form of DNA vaccination is efficient not only against tumors or metastasis in the gut, the peritoneal cavity and the draining area of the portal vein, but efficiently initiates a systemic immune response (93-95) with induction of memory T cells (96). The efficacy of the anti-tumor response can be further improved by modulating the molecular form of the expressed tumor antigen (97), by transformation of the bacteria with chimeric DNA (98-100), which directs the nascent protein into the MHC class II processing pathway or consists e.g., of the tumor antigen and a cytokine, or by the use of selected promoters (101).
RNA Vaccination
RNA as a tumor vaccine has first been used when pulsing DCs in vitro with total RNA of tumor cells (102). RNA has the advantage of being amplified, thus providing an unlimited source of tumor antigen (69). Meanwhile, the applicability of RNA vaccination in vivo has been demonstrated in an elegant study comparing liposome encapsulated condensed RNApeptide complex, condensed RNA-peptide complex without liposome and naked, unprotected RNA. All three preparations lead to the induction of CTL and to antibody production. The authors conclude that RNA vaccines have the same advantages as DNA vaccines but lack the potentially harmful effect of DNA integration into the genome (103).
Further improvements can be achieved by making the genetic vaccine "self-replicating" by using a gene encoding RNA replicase. Replicase containing RNA vectors are significantly more immunogenic than conventional plasmids. Cells transfected with those vectors produce large amounts of antigen for a short time and then undergo apoptosis. It is suggested that death results from the production of doublestranded RNA intermediates, which have been shown to activate DCs most efficiently (88).
Protein/Peptide Vaccination by Loading Dendritic Cells
Vaccination with tumor extracts, tumor-associated proteins and peptides derived thereof has become an important tool after succeeding with the in vitro generation of DCs from bone marrow cells or from peripheral blood leukocytes (104, 105). An important prerequisite for successful vaccination with DCs is the mode of their in vitro activation (106). Ex vivo loaded DCs have been shown to most efficiently activate T cells (107-109). In view of the expanded knowledge of peptide motifs presented by different MHC class I haplotypes (110-113), the majority of animal studies as well as first clinical trials have used such peptides for loading DCs. Alternatively, DC have been pulsed with tumor extracts or have been fused with tumor cells (114-117). Clinical trials have already been performed with different tumor types, such as melanoma, lymphoma, non-Hodgkin's lymphoma, prostate cancer and renal cell cancer. So far quite diverse protocols have been used for vaccination (20), but none of the clinical studies reported severe side effects (104, 108, 109, 114, 116, (118) (119) (120) (121) (122) (123) (124) (125) (126) (127) .
Application Route and Delivery Systems
In view of the diversity of protocols used for vaccination, experimental studies to comparatively explore different modes of antigen presentation, dose and route of application have gained considerable importance. We can be very brief on these aspects, because they have been mentioned already in the context of the various tumor antigens. Several studies using DNA, RNA or peptide/protein naked or delivered by classical APC described the superiority of the intradermal or subcutaneous route as compared to the intravenous application (128-131).
As outlined in an elegant study by the Zinkernagel group (132, 133) , even the failure to provoke an anti-tumor response in the native host may be site-related inasmuch as many tumors are ignored by the immune system solely due to the fact that they are located at an "immune-privileged" site.
Delivery systems too, have already been mentioned and discussed. In most instances, "packaging" of the antigen is advantageous. Simply for the ease of handling, tumor cells have originally been used as delivery system, but have largely been replaced by professional antigen presenting cells like B cells and DC, which will be fused with tumor cells, loaded with peptide/protein or tumor cell lysate or infected with tumor RNA or DNA (69, (134) (135) (136) (137) (138) (139) (140) (141) (142) (143) . Lately, bacteria also have come into discussion. By transformation with eukaryotic expression vectors, which allow the transcription of the inserted gene in host cells, an easy to handle and comparably cheap vaccination regimen has been created (89, 144-147).
Response Elements: Activation of Cytotoxic and/or Helper T Cells
It is well known that the initiation of a sustainable immune response requires an activation of TH cells (148-150). Thus, activation of CTL will be optimized if the right cytokines are provided by TH cells (149, 150) . Activation of B cells also depends on the provision of helper factors (151). Most importantly, recruitment and activation of non-adaptive defense mechanisms, presented mainly by NK cells, monocytes/macrophages and granulocytes can be achieved by activation of TH cells (152-154). By the concomitant activation of B cells and the production of antibodies, defense activities are further augmented via antibody-dependent cellular cytotoxicity, Fc-receptor mediated activation of macrophages and activation of the complement cascade (155-161). Only recently have these aspects been taken up in a synoptic manner in tumor immunology. Thus, it has been demonstrated that transfection of a tumor cell with MHC class II molecules and B7.1 cDNA initiates an efficient TH response (162, 163) , where presentation of peptides by the transfected MHC class II has been significantly increased (164, 165) . Only by the activation of a MHC class II guided TH response could the development of metastases be suppressed (162, 166) . Furthermore, it has been reported that a human melanoma line, which expressed both class I and class II antigens efficiently presented ras-derived peptides to a TH line (167) and regression of renal cell carcinoma after vaccination with pulsed DC was only observed when a TH type 1 response was induced (168). Trials to redirect endogenously derived peptides to the lysosomal compartment by linking LAMP-1 or the invariant chain (of class II) to the antigen, also supported induction of a TH response (168-171). Finally, protection against a virally induced tumor could only be achieved by vaccination with a viral TH epitope (172) and even with a subcutaneous immunization of class II restricted peptides of HER-2/neu a systemic response could be obtained (173). These studies support the concept that induction of a TH response may be a most desirable goal in cancer therapy. The technical difficulties hampering the exploration of a TH-guided vaccination response have nowadays mostly been mastered. The knowledge of peptide motifs presented by class II (25, 62, 111, 114, 169, 174, 175) , the in vitro generation, maintenance and expansion of APC, which efficiently take up exogenous antigen and present it on class II (176-179), like immortalized B cells (180, 181) or in vitro generated DC (105, 182), are important components in achieving improved efficacy of vaccination. First results are promising: Loading of DCs with class II restricted MAGE-3 peptides induced a potent CD4 T cell-mediated cytotoxic response (183). Loading of DCs with gp100 or gp100 derived peptides ex silico predicted to bind to MHC class II molecules initiated a TH response which sufficed to retard the growth of a malignant melanoma in the SCID mouse (184, 185) . Induction of a CTL response against Muc1 was significantly increased when DCs were loaded in addition with a pan-HLA-DR epitope (186). It is no question that cancer vaccination protocols require further optimization. These include an ongoing search for tumor antigens, which induce a vigorous T cells response, optimizing the delivery systems with respect to the efficacy of antigen presentation depending on the form of the antigen and the route of application, e.g., in vivo expression of defined antigens, their uptake and processing by APCs (67, 187), the transport of proteins/peptides from the site of injection towards the draining lymph node, and the activation and expansion rate of T cells (133, 188, 189) . Finally, it will probably be essential to carefully control the individual patient's response and, probably, to modulate the vaccination regimen according to the individual response profile.
Strategies of Immune Modulation to Support Vaccination Efficacy
Taking into account that the first clinical trials of tumor vaccination did not meet expectations, it becomes obvious that the tumor patient's immune system requires, besides the initial vaccination trigger, further support by adjuvant regimen (10, 190, 191) . The field of immune modulation dates back long before active vaccination regimen were considered. Here, only modalities which might support active vaccination will be mentioned.
Transfer of Activated Effector Cells
The transfer of activated effector cells may provide a supporting bridge during the initial period of vaccination until sufficient newly emerging effector cells are available. The bridging function may be of particular importance in the context of allogeneic reconstitution after myeloablative conditioning, where weeks to months will pass before patients can be considered as immunocompetent, the process of regaining of immunocompetence being known to be further retarded by many tumors. Excellent reviews in the field have recently been published (40, 192) . The idea behind the adoptive transfer of ex vivo activated and/or expanded tumor-specific CTL or lymphokine activated killer cells (LAK), particularly if derived from tumor-infiltrating lymphocytes (TIL), is the immediate immune attack of residual tumor cells after debulking surgery (192) (193) (194) . Possible hurdles like limitations in the survival of effector cells, in the maintenance of an activated state, and in the recirculation of the in vitro expanded cells, can hopefully be solved by means of several immunomodulatory protocols (195) (196) (197) (198) (199) (200) (201) ). Yet, the demanding technology for in vitro generation and expansion of specific CTL is a limiting factor, which restricts the approach to a minority of cancer patients.
A refined version of T cell transfer utilizes T cells with an artificial receptor. Conceptually, the artificial T cell receptor should confer tumor-specificity onto naive T lymphocytes. This can be achieved by the introduction of a chimeric receptor, which consists of a single-chain antibody fragment that is linked to the zeta chain of the receptor complex, the antibody moiety recognizing a membrane antigen of the tumor. Alternatively, TCR αβ chains specific for an MHC class I or class II presented tumor-peptide can be introduced. Also, T cell transfection with TNF or other cytokines are supposed to support the local anti-tumor response (62).
Antibodies/Bispecific Antibodies
Much hope has originally been given to cancer therapy with monoclonal antibodies (mAB) (202). The dominating idea was that mABs would specifically bind to tumor antigens and trigger immune cytolysis according to the mechanisms of either complement-mediated lysis or antibody-dependent cellular cytotoxicity. The initial stumbling block, the mouse nature of monoclonal antibodies which gave rise to vigorous production of anti-mouse immunoglobulin (HAMA), was overcome by "humanizing" the murine antibodies (reviewed in 203). At present, mAB, idiotype specific antibodies (204, 205) and antibodies recognizing leukocyte differentiation markers, have been successfully introduced into clinical trials in hematological malignancies. With a mAB recognizing the B lymphocyte differentiation antigen CD20, good responses have been obtained in B cell lymphoma and low grade follicular lymphoma, which are considered as incurable (206, 207) . With respect to solid tumors, mAB-based therapy has its strength in the setting of minimal residual disease as an adjuvant therapy (208). There is evidence that antibodies recognizing and blocking growth factor receptors may be of particular relevance. The lead candidate is the antibody Herceptin® against c-erbB2 (HER-2) which has been registered in the USA and Europe for second and third line treatment of breast cancer. A number of similar antibodies are directed against the EGF receptor (c-erbB1) which is overexpressed on most epithelial tumors (209, 210). These antibodies have been shown to block autocrine loops and abrogate cellular salvage reactions, thus exhibiting synergy with chemotherapy or radiation (211). Particularly for the treatment of colorectal cancer the mAB 17-1A (Panorex) which recognizes the panepithelial antigen Ep-CAM is used as adjuvant treatment after surgery (212). There are reports on reduction in relapse and mortality (213). Panorex has been suggested to initiate an immune network cascade (214, 215) and to support, in combination with GM-CSF, induction of a T cell response (216).
As mentioned above, the transfer of in vitro activated and expanded cytotoxic lymphocytes, LAK as well as CTL, revealed less promising results than expected (217, 218), because the transferred lymphocytes rapidly sequestered in the spleen (219, 220) . This finding initiated a second generation of antibody-based therapies. By the use of a bispecific antibody, which binds with one arm the effector cell and with the second arm the tumor, the problem of sequestration of effector cells in the spleen can partly be circumvented. Single bispecific mABs allow for effector cell targeting, they are insufficient for effector cell activation (221, 222) . However, by the use of a set of bispecific mABs which bind to the tumor cells, the T-cell receptor/CD3 complex and a costimulatory molecule on the T-cell, the requirement for reactivation as well as targeting of the transferred effector cells towards the tumor can be fulfilled (221, 222) . In fact, preclinical trials with a set of two bispecific mABs have demonstrated convincing therapeutic effects supporting the view that through a set of two bispecific mAB or through a trispecific mAB, effector cells may become re-targeted and reactivated (222, 223) . In most studies lymphoid tumors were targeted and/or LAK cells were used as effectors (224). More recent trials confirmed the efficacy of sets of bispecific antibodies also in the treatment of solid tumors (225-227) and provided evidence that antigen-specific CTL can be superior to LAK (86, 228) . Coupling of effector domains, e.g., enzymes for converting prodrugs, radionuclides, toxins and immunostimulators, provides an alternative approach to bispecific antibodies attempting to increase the functional potency of mAB (197, 203, 229, 230) .
Cytokines and Antibody-cytokine Fusion Proteins
Cytokines are without question most potent immunostimulators. Yet, they are short lived and function under physiological conditions in an autocrine or paracrine fashion (231). This implies that after systemic, high dose application of e.g., IL1, IL2, IFNα, IFNγ, TNFα and IL12 severe side effects are observed (232-234). Thus, the systemic use of these cytokines was only beneficial in niche indications like e.g., metastatic melanoma, renal cell carcinoma and some hematological malignancies (235-237). Some hematological malignancies are also systemically treated with IFNα, G-CSF and GM-CSF (237). The localized application is by far less burdened with side effects and is practiced in the therapy of malignant melanoma using TNFα for isolated limb perfusion (238) and for the treatment of liver metastasis via injection in the portal vein (239). Bladder and thyroid cancer are also treated via direct injection of TNFα into the respective organs (240, 241).
To circumvent the limited operational use of cytokines due to side effects, alternative application modalities have been elaborated. Cytokine-based tumor therapy concentrates on either gene transfer (see above) using mainly IL-12 and GM-CSF as molecularly defined adjuvants (49, (242) (243) (244) (245) (246) or on targeting the cytokines by fusing them to an antibody against a surface molecule on the tumor cell. So far, mostly IL2, IL8, IL12 and TNF have been fused to mAB (247-251). Important features of these fusion proteins are their prolonged half life as compared to cytokines by themselves, and the redirection and retention of the cytokine at the tumor cell surface. The local availability of a cytokine is expected to obviate the requirement for a costimulatory signal of immune activation (251). IL-2 fusion proteins have been reported to induce the activation of CTL (195, 248, 249, 252) , of lymphokine activated killer cells (253, 254), of TH cells (255) and, under appropriate circumstances, of a memory response (256). Activation of neutrophils, monocytes, and B cells has also been described (247, 250). Thus, cytokine fusion proteins can initiate the natural cascade of immune response events. Having activated the intratumoral lymphoid cells, which may be CTL, LAK or monocytes, a few tumor cells may be lysed and tumor cell debris encompassing the whole complement of tumor antigens can be transported to and be presented in the draining lymph node. At this point, the response should become systemic and yield a memory that encompasses cells endowed with a migratory capacity. The validity of the hypothesis could be confirmed in a SCID mouse model with a human tumor transplant (255, 257) . Finally it should be mentioned that a high level of intratu-morally available cytokine has been shown to counterbalance immunosuppression and to reverse escape strategies of the tumor cells (258).
In a second type of chimeric proteins, the antibody is fused to a superantigen. These fusion proteins have yielded similar convincing therapeutic effects as antibody cytokine fusion proteins (259, 260) . Taking the efficacy of genetically engineered antibodies and of antibody conjugates, it could be well justified to include antibody treatment as an adjuvant therapy in tumor vaccination (261).
Immune Response Modifiers
Some 20 years ago, the term "biological response modifiers" has been coined for immunomodulating substances with a potential in tumor therapy. Most "biological response modifiers" were based on bacterial preparations, e.g., on cell wall-derived lipopolysaccharides. Their therapeutic efficacy is largely due to the induction of cytokines (262) and it has been suggested to name these cytokine-inducing bacterial virulence factors "modulins" (263). A few more recently established response modifiers should be mentioned. Liposome encapsulated muramyl tripeptide phosphatidylethanolamine targets the response modifier to monocytes and macrophages and initiates proinflammatory cytokine production (264). KRN7000 is a alphagalactosylceramide, which strongly enhances NK activity (265). Swainsonine, an inhibitor of glycosylation, also enhances NK and LAK activity and leads to upregulation of the IL2ß chain receptor expression on these cells (266). My-1 is a DNA fraction of mycobacterium bovis BCG (267), which increases immunoreactivity in cancer patients by mechanisms different from those of bacterial cell wall products (87). Probably one of the most efficient adjuvants are tumor derived heat shock proteins, such as hsp70, hsp90, gp96/grp94. Heat shock proteins are the natural chaperons of peptides and as such reflect the immunogenic repertoire of tumor cells as presented in MHC class I molecules (268, 269) . The second point of attractiveness is their power as adjuvant (270). Accordingly, heat shock proteins should be applied individually specific and there are refined protocols to obtain a sufficient yield from tumor tissue for vaccination (271). Therapeutic trials mostly have been concerned with solid tumors (272, 273 ), yet vaccination with heat shock proteins appears to be promising in leukemia, too (274).
Taken together, present day immunomodulation strategies have a principally different orientation. Originally, immunomodulators were selected for the stimulation of nonadaptive immune defense. The new generation of immunomodulators are conceived to support and corroborate with the adaptive immune response and, thus, should be included in active vaccination protocols.
Hazards in Tumor Vaccination
Without question, the last two decades have provided the prerequisites for successful immunotherapy of cancer. A considerable number of tumor-associated and tumor-specific antigens have been cloned, immunogenic peptides presented by MHC class I and class II antigens have been identified, antigen presenting cells can be created and expanded in vitro, activation and expansion of tumor-specific T cells can efficiently be induced and a new armoury of adjuvant regimen has been established. Still the clinical success remains far behind expectation. This is due, at least partly, to the nature of tumor cells and the microenvironment created by the tumor. Thus, for successful active immunization, understanding of immunoevasive maneuvers is an essential prerequisite (275). Drawbacks in tumor vaccination have to be viewed from two sides, the tumor and the immune system.
Tumor Escape Mechanisms
The nascent tumors can exploit a large array of mechanisms to suppress or evade an immune attack. The most prominent escape mechanisms are categorized in 2 groups which provide passive resistance or active counterattack. With respect to the former, it is mainly the loss or low expression of MHC class I antigens, which hampers an efficient attack by CTL. This aspect has been recently reviewed in detail with an elucidation of the most frequent alterations and the implicated mechanisms (276). Here it should just be pointed out that activation of helper T cells and recruitment of non-adaptive immune defense may provide a means of circumventing this tumor escape mechanism. A second phenomenon which can significantly reduce the efficacy of an immune attack is the modulation of tumor antigen expression in response to such an attack. Tumor antigens have been described to be shed, to be transiently downmodulated or to become lost in the presence of CTL with high avidity (16, 17, 217, 277, 278) . Thus, to avoid the pitfalls resulting from heterogeneous antigen expression (279) and from partial loss of antigens under the selection pressure of a successful immune response (280, 281) , it is desirable that vaccination encompasses a panel of antigens that represents a given tumor type.
Beyond this, tumors can produce substances, which interfere with the induction of an immune response, e.g., they may produce cytokines which downmodulate an immune response (282, 283) . Finally, the tumor may counterattack the immune system by upregulating FAS (284, 285), rev. in (275) .
Tolerance and Autoimmunity
Many of the tumor antigens considered for tumor vaccination are rather tumor-associated than tumor-specific. This implies that tolerance of the T cell compartment can become an impor-tant feature (18, 211, (286) (287) (288) (289) . The problem can possibly be circumvented by focussing on moderate to weakly immunogenic entities concomitantly with strong and repeated stimulation in combination with the appropriate adjuvant (211, 286, (288) (289) (290) (291) . Also, if the first encounter of the immune system with the antigen occurs in an inappropriate context, e.g., in the absence of costimulatory molecules, a state of anergy may have been created. Repeated stimulation in combination with adjuvants, heterogenization of the antigen and/or provision of IL-2 and IL-12 have been described to override such an anergic state (19, 215, 286, (292) (293) (294) (295) . On the other side of the coin another obstacle is encountered. Vaccination with tumorassociated differentiation antigens may induce an autoimmune response which damages normal tissues (211, 289) . Though researchers and clinicians are well aware of this potential pitfall, so far, no serious side effects have been observed (278), except for vitiligo after vaccination with the melanocyte differentiation antigens tyrosinase and gp75.
These hazards in tumor vaccination were not unexpected. Nonetheless, tumor antigens and vaccination strategies had to become elaborated before it now will be possible to focus on how to sustain an efficient anti-tumor response in the counteracting tumor environment (296).
Active Tumor Vaccination After Allogeneic Bone Marrow Transplantation

Allogeneic Bone Marrow Cell Transplantation
The Prospects of Non-myeloablative Conditioning
Allogeneic hematopoietic stem cell transplantation is considered as a potentially curative option for patients with malignancies of the hematopoietic system or with solid tumors even after exhaustion of conventional therapies (13, 14, 297, 298) . Because of the high toxicity of the myeloablative conditioning regimen, allogeneic hematopoietic stem cell transplantation could be given only to young patients in good health condition (299) (300) (301) . Only recently has it been explored in animal models and could be confirmed in first clinical trials that the transfer of allogeneic hematopoietic stem cells does not essentially require myeloablative conditioning. The transfer of allogeneic hematopoietic stem cell after non-myeloablative pretreatment does not require hospitalization and will be tolerated also by elderly patients and patients in poor health condition (15, (302) (303) (304) (305) (306) (307) (308) (309) . The problem of graft versus host disease (GvHD) remains and also the problem, of how to reduce GvHD without reducing or eliminating graft versus tumor (GvT) reactivity. Furthermore, conditions to support engraftment have to be elaborated for the non-myeloablatively conditioned as well as for the myeloablatively conditioned patient. One possible drawback of allogeneic transplantation of the non-myeloablatively conditioned host will be the possibility of active graft rejection by the host (310-316). I want to stress an additional point. It was long believed that exclusively high dose chemotherapy and/or high dose irradiation exerted a therapeutic effect and BMC reconstitution was solely considered to replace hematopoiesis. For this reason, allogeneic BMC reconstitution was mainly considered as therapeutic option in hematological malignancies (317). However, with the option of allogeneic reconstitution after non-myeloablative conditioning it became apparent that the allogeneic graft significantly contributes to the therapeutic efficacy. This implies, that allogeneic BMC reconstitution after non-myeloablative conditioning should be equally efficient in hematological malignancies and solid tumors (318-320). So far this option has mainly be explored in renal cell carcinoma, which are frequently chemo-and radiation resistant. Preclinical as well as clinical studies yielded encouraging responses (321-323).
Strategies to Reduce Graft Versus Host Disease
Originally it has been supposed that GvHD is mediated by allogeneic T cells present in the bone marrow cell graft and that, consequently, GvHD should be abrogated or reduced by graft T cell depletion (324-327). Unfortunately, graft T cell depletion is frequently accompanied by a failure of engraftment (328-331). Thus, alternative strategies had to be explored which should be based on a basic understanding of GvHD. Ferrara describes in an elegant review the development of GvHD as a multistep process (299).
Step one is based on the conditioning regimen which may damage host tissue and amplify antigen presentation to the allogeneic donor T cells. This aspect, fortunately, should be less impressive in the non-myeloablatively than the myeloablatively conditioned host (332).
Step two involves the donor T cell activation and has to be considered as rather complex, because besides the activation of alloantigen-specific T cells, inflammatory responses will take place. This may be initiated by the destruction of the gut epithelium, which will be accompanied by the release of inflammatory cytokines and mediators such as endotoxin. Taken together, elements of the non-adaptive immune system may further stimulate the allogeneic response and effector cells of the adaptive and the non-adaptive immune system may coordinately damage additional organs, e.g., the liver. Thus, induction of tolerance towards alloantigens remains one of the most elusive goals in allogeneic hematopoietic stem cell transplantation (333), although considerable progress has been made by a better understanding of mechanisms of peripheral tolerance induction (334-336). Based on this knowledge, blockade of costimulatory molecules or the infusion of regulatory T cells are nowadays considered as an alternative to T cell depletion (328, (337) (338) (339) . A few modalities suggested to efficiently interfere with lethal GvHD should be mentioned. Concomitant depletion of CD4+ T cells and the application of a low number of CD8+ T cells has been described to be favor-able for graft acceptance. It is discussed that CD4+ cells are essential for the development of GvHD, whereas CD8+ T cells may provide factors allowing engraftment (340). Alternatively, a selective depletion of alloreactive T cells has been suggested (341, 342) . Most concepts deal with the blockade of T cell activation directly or via costimulatory molecules either by the application of antibodies like anti-αβ-T-cell-receptor, anti-CD40L or or by the use of low molecular weight substances as competitors, e.g., a CD4-CDR3 peptide (328, (346) (347) (348) .
Besides T cell-mediated reactivity, NK-mediated alloreactivity can play an important role in . The long known phenomenon of hybrid resistance (355) could recently be clarified -at least in part -by the identification of killerinhibitor receptors (356) (357) (358) (359) . Killer-inhibitor-receptors recognize certain MHC alleles (360) (361) (362) (363) (364) . Via binding of these receptors, NK cells receive signals which interfer with activation of the lytic machinery (358, 363, (365) (366) (367) and detach from the targeted cell (368). The signals initiated via the inhibitory receptors are dominating (129, (369) (370) (371) (372) (373) . This implies that NK cells in the allogeneic hematopoietic graft may not be inhibited and may develop cytotoxic activity against the host (354, (374) (375) (376) (377) . One possibility to cope with this problem would be occupancy/activation of killer inhibitory receptor (349, 350, (378) (379) (380) . On the other side, it has been reported that after the transfer of fully haplotype mismatched BMC a wave of alloreactive NK cells mediated a strong GvL effect without evidence for GvHD (354). Instead, a host receiving a pre-transplant infusion of NK cells was protected from GvHD (381). As a possible mechanism of the NK-mediated GvHD protection, it is discussed that NK cells may have eliminated antigen presenting cells of the host. Increasing knowledge on the balance between signals transmitted by inhibitory and activating NK receptors as well as on the ligands of inhibitory and activating receptors is required, to allow the design of transplants where NK reliably contribute to GvT reactivity while preventing GvHD (382).
The described features of GvHD are rather independent of whether the host has been myeloablatively or non-myeloablatively conditioned, except that in the latter case one of the initial stimuli provided by damaged host tissue will be avoided or at least be reduced. Yet, after non-myeloablative conditioning the problem arises of how to avoid that host hematopoietic cells destroy the graft.
Conditions Favoring Engraftment and Preventing Graft Rejection
During the past few years there has been an explosion of knowledge of nonablative allogeneic stem cell transplantation, which relies more on the creation of "immunological space" than the traditional approach which created "physical space" (383). The preparative regimen, suitable indications as well as preliminary results in hematological and solid malignancies have been reviewed recently (15, 302, 303, 331, (384) (385) (386) (387) . Here we want to point out some of the remaining problems, which to solve will require a more detailed understanding of the underlying principles, particularly the related immunological phenomena.
As already discussed, T cells in the allogeneic transplant support engraftment. This has also been confirmed in clinical trials, which indicated, in addition, that the problem cannot be circumvented by the transfer of a low number of CD3+ cells. The majority of patients receiving a T cell depleted graft together with a low number of CD3+ cells showed a quick recovery of hematopoiesis, but only transiently a state of chimerism. Thus, the addition of CD3+ cells did not support long term engraftment. The therapeutic efficacy of the regimen was accordingly negligible (388). Thus, further exploration on the underlying molecular mechanisms of engraftment are needed to design strategies for safe engraftment. Recently, it has been shown that long lived plasma cells homing into the bone marrow express a special profile of chemokine receptors (389). Elaboration of the profile of chemokine receptors on hematopoietic stemand progenitor cells as well as their ligands in the bone marrow milieu may provide clues how to solve this task.
Another problem of particular importance in the non-myeloablatively conditioned host relies on the possibility of active elimination of the graft by remaining host cells. While T cell reactivity is mostly coped with by accompanying immunosuppressive drugs, NK cells of the host, as outlined above for NK cells in the graft, can severely interfer with graft acceptance. The problem can be attacked by selective depletion of host NK cells before transplantation. We and others could show that this is not accompanied by any disadvantage, but significantly increases the rate of engraftment with establishment of a persisting hematopoietic chimerism (313, (390) (391) (392) (393) (394) (395) (396) (397) .
Vaccination After Allogeneic Bone Marrow Cell Transplantation
How to Maintain Graft Versus Tumor Reactivity?
The concept of allogeneic reconstitution after non-myeloablative conditioning is based on the observation that an immune-mediated graft-versus-tumor reaction plays a pivotal role in the curative potential of allogeneic stem cell transplantation (398). However, there remains the problem of reducing GvH reactions, while maintaining the GvT reactivity. As mentioned above, it has been observed in clinical studies that donor lymphocyte infusion after allogeneic reconstitution may suffice to eliminate a recurrent tumor without inducing severe GvHD. Yet, these observations are incidental and the underlying mechanisms have not yet been clarified (309, 399, 400) . Nonetheless, it was those findings which led to the suggestion that there is a selective contribution of GvT reactive T cells independent of and besides GvH reactive T cells (401). In addition, it has been suggested to selectively support the GvT reaction by the transfer of subpopulations of T cells, that regulate GvHD, but support GvT reactivity (404). Many groups are engaged in separating GvT from GvH reactivity by trials to elucidate distinct pathways of stimulation or by searching to unravel potentially different effector pathways of host and tumor-specific T cells (403, 404) . Though grafted allogeneic T cells undoubtedly contribute to tumor defense, I want to focus on the antitumor response of newly appearing T cells, which I and others consider as a most promising baseline for active vaccination after allogeneic reconstitution of a non-myeloablatively conditioned patient. Before discussing this aspect, the possible contribution of NK cells in GvT reactivity should be mentioned. It was already pointed out that in the fully haplotype mismatched host, donor NK cell can significantly contribute to the elimination of leukemic cells (354, 381) . In line with this report are studies showing that the blockade of KIR inhibitory receptors augments the antileukemic activity of NK cells in the allogeneically reconstituted host (405, 406) . Modulation of activating NK receptors may offer an additional option to support GvL reactivity (407, 408) .
Possible Modes of Vaccination in the Allogeneically Reconstituted Tumor Bearing Host
In animal models, it has been described that host, anti-donor immune lymphocytes after BMC transplantation improved the rate of tumor rejection without increasing the rate of lethal GvH disease (409). The rate of tumor rejection could also be improved by the application of tumor-specific antibodies (410) or by tumor-specific T cells (411). Furthermore, potent anti-tumor effects were seen by vaccination with GM-CSF transfected tumor cells, when vaccination was started 6 weeks after the transfer of T cell-depleted allogeneic BMC. Notably, when mice were reconstituted with non-depleted BMC, lethal GvH reactivities developed after vaccination (412). Also, vaccination with tumor cells after allogeneic reconstitution of the lethally irradiated host were only therapeutically efficient when mice were vaccinated one month after reconstitution (413). Both these features are well in line with the concept that vaccination preferably should support activation of donor T cells, which are host-tolerant and host-restricted.
Allogeneic T cell progenitors which matured in the host thymus will recognize the hosts' MHC as self and there is convincing evidence that these host-tolerant and host-restricted T cells respond to the tumor (14, 301, 302, 386, (414) (415) (416) (417) (418) (419) . The reasons for these could be several. First, a peptide presented in the host MHC may be more immunogenic than a peptide presented in the donor MHC. Second, peptides derived from a differentiation antigen might not induce a response in the autologous system, because immune cells have been confronted with the peptide during ontogeny. Yet, the allogeneic T cells, which matured in the adult organism, may not have seen differentiation antigen-derived peptides. Third, autologous T cell may be ignorant towards a solid tumor because of a failure of contact. In the allogeneically reconstituted host, due to unavoidable minor GvH reactions, tumor cell debris will be presented in large enough quantities to allow induction of a response. Fourth, the phenomenon of anergy induction by presentation in the absence of costimulatory molecules may also be avoided by the presentation of tumor cell debris by host APC. This should account for solid as well as hematological malignancies. Fifth, and likely of major importance, the above outlined scenario of a mixed allogeneic and inflammatory reaction may add to create an environment strongly supporting the activation of an anti-tumor response. It should be remembered in this context that the activation of helper T cells and the recruitment of non-adaptive defense mechanisms appears to be at least as important as the generation of tumor-specific CTL for an efficient immune attack. Whether these hypotheses hold true and whether additional factors may support GvT reactivity after establishment of full donor chimerism remains to be explored. According to our own studies in a murine renal cell carcinoma, the survival rate could be significantly improved without any aggravation in GvHD when host-tolerant, donor-derived cells were primed with tumor-lysate-loaded host-derived DC (unpublished finding). Taken together, first experimental and clinical experiences are promising and set a solid ground for allogeneic reconstitution of the non-myelablatively conditioned host as part of an active tumor vaccination regimen (309, 387, 397, 412, 413, (420) (421) (422) (423) (424) (425) (426) (427) .
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Technology in Cancer Research & Treatment, Volume 2, Number 3, June 2003 Figure 1 : Non-myeloablative conditioning of the allogeneically reconstituted host as a superior platform for active vaccination: Newly emerging donor derived T cells will pass host-and donor-derived hematopoietic cells when migrating from the thymic cortex towards the medulla. Thus, T cells will become tolerized for host self antigens presented by the host's MHC. Instead, the thymus will be devoid of host hematopoietic cells after mye-loablative conditioning and donor-derived thymocytes will only become tolerized towards host self antigens in the context of the donor's MHC, i.e. mature donor-derived T cells may still recognize self antigens presented by the host's MHC. Also, only in the non-myeloablatively conditioned host, donor-derived T cells can become activated by host-derived APC presenting tumor antigen-derived peptides.
Conclusion
Although clinical results obtained so far with therapeutic vaccination in cancer remain behind expectation, I still consider them as encouraging. Without question, further efforts in optimizing vaccination protocols are needed. It appears rewarding to focus on the careful elucidation of optimized strategies for presenting tumor antigens to immune effector cells as well as on supporting the recruitment of the "complete" immune defense scenario including adaptive and nonadaptive defense elements. Particularly, allogeneic reconstitution of the non-myeloablatively conditioned host may provide a natural means of increasing the immunogenicity of tumor antigens and, most importantly, induction of tolerance and anergy may not be of relevance in tumor vaccination of the allgeneically reconstituted host. Zoller 
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